Therefore, in this experimental model we adopted a modified version of the LysiSpot assay, based on a non viral transfection method to obtain ß-gal-expressing tumor target cells, combined with an IFN-γ ELISpot in a dual-colour testing, aiming at developing a method to analyze tumour specific immune responses. The gene discussed is IFNG; the disease is neoplasm.